Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Transparency for Better Science

Posted on February 10th, 2016 by

Pharma R&D

trans

I like to think of scientific discovery as not unlike parenthood: scientists create a piece of knowledge (like a child), and then release it to its own life in the world (a grown-up child), and, often, that piece of knowledge informs the Continue reading “Transparency for Better Science” »

R&D? S&D? It’s About Science

Posted on February 9th, 2016 by

Pharma R&D

science

Last month’s announcement that industry giants AstraZeneca, GSK, and Johnson & Johnson had teamed up with three well-regarded UK universities –Imperial College London, University College London, and University of Continue reading “R&D? S&D? It’s About Science” »

Is Pain a Gender Issue?

Posted on February 8th, 2016 by

Chemistry

newron

How sensitive are you to pain? Many women feel that men are more sensitive to pain (or at least make more fuss about it). They often cite childbirth as one of the many reasons females are so much tougher than males. Continue reading “Is Pain a Gender Issue?” »

Outside Perspectives Beget Better Outcomes

Posted on January 26th, 2016 by

Pharma R&D

theory_wide-c844f178048a2684625fb1a1fb5c4c4e42fc124a-s6-c30

My favorite quote about why drug discovery, despite very productive decades of productivity and innovation, has seemed to have reached the drought is from Ashutosh Jogalekar in Scientific American blog: Continue reading “Outside Perspectives Beget Better Outcomes” »

Gender gap, the leaking pipeline of R&D

Posted on January 21st, 2016 by

Pharma R&D

R_D_Solutions_blog_mind_the_gap_DIGITAL

I guess we all worked out that half of the people on this planet are male and the other half are female. If you even sporadically read the papers you must have stumbled upon some sort of article quoting numbers such as Continue reading “Gender gap, the leaking pipeline of R&D” »

EMA Yearly Update on MLM – highlights and next steps

Posted on January 19th, 2016 by

Pharmacovigilance

pills

EMA  Pharmacovigilance Programme Update Issue 6 – Preparing for Business Change

Since July 2014, EMA provides quarterly Pharmacovigilance Programme Updates to Marketing Authorisation Holders (MAHs). Continue reading “EMA Yearly Update on MLM – highlights and next steps” »

  1. 1
  2. …
  3. 48
  4. 49
  5. 50
  6. 51
  7. 52
  8. …
  9. 55


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.